Patient Guide: A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 153 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06149286
Status: 🟢 Enrolling Now
Condition: Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL)
Phase: PHASE3

Where You Can Participate

This study is available at 153 locations across the country.

Top locations include:
  • • Los Angeles, California
  • • Plantation, Florida
  • • Indianapolis, Indiana
  • • And 150 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma - Join Clinical Trial NCTNCT06149286

How to Join This Clinical Trial - NCTNCT06149286

Learn how to participate in this PHASE3 trial studying an investigational therapy for Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL). This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL). Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL)
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06149286 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 153 locations. Find a study site near you:

Clinical Research Site

Los Angeles, California 90095 - United States

Status: RECRUITING

Clinical Research Site

Plantation, Florida 33322 - United States

Status: RECRUITING

Clinical Research Site

Indianapolis, Indiana 46202 - United States

Status: RECRUITING

Clinical Research Site

Hattiesburg, Mississippi 39401 - United States

Status: RECRUITING

Clinical Research Site

Stony Brook, New York 11794 - United States

Status: RECRUITING

Clinical Research Site

Westbury, New York 11590 - United States

Status: RECRUITING

Clinical Research Site

Waukesha, Wisconsin 53188 - United States

Status: RECRUITING

Clinical Research Site

Liverpool, New South Wales 2136 - Australia

Status: RECRUITING

Clinical Research Site

Waratah, New South Wales 2298 - Australia

Status: RECRUITING

Clinical Research Site

Benowa, Queensland 4217 - Australia

Status: RECRUITING

And 143 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL):

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships